Briefing: Opioid Use Disorder Medication Access Program

Research Focus

This program targets the opioid crisis by expanding access to medications for opioid use disorder (MOUD)—primarily methadone, buprenorphine, and naltrexone—and supporting evidence-based treatment and recovery infrastructure. The funder seeks research, implementation, and service delivery innovations that increase MOUD availability, reduce barriers to treatment engagement, and lower rates of illicit opioid use, prescription opioid misuse, and overdose mortality. Projects may span clinical pharmacology, health services research, implementation science, behavioral interventions, and policy analysis to strengthen treatment systems across diverse populations and settings.

At a Glance

• Who can apply: Not stated
• Funding & project length: Not stated
• Award / mechanism: Not stated
• Key dates: Not stated
• Best fit for: Addiction medicine, public health, and implementation science researchers focused on opioid use disorder treatment access, medication-assisted therapy, and overdose prevention

Missing critical details: Eligibility criteria, funding amounts and project duration, application deadlines, and award type/structure. Consult the full FOA for these essential details before deciding to apply.